Encoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
ParticipantI
Invus
Activity from announced rounds
Activity in this selectionsamsung-venture-investment-a2889bb3
- Rounds participated in
- 7
- Confirmed lead rounds
- 0 6 roles undisclosed
- New companies
- 7 First participation on record · 0 follow-on
- Funding in participating rounds
- $1.3B 6 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
7 in this selectionLifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedCity Therapeutics
Develops next-generation RNAi therapeutics and engineering platform for multiple disease areas
$99.5MSeries B
Role not disclosedContraline
Develops hormonal and non-hormonal male contraceptives for men and couples globally
$92.5MSeries B
Role not disclosedFlexiv
Develops and manufactures adaptive robots for complex tasks
UndisclosedStrategic
Role not disclosedMirador Therapeutics
Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases
$250MSeries B
Role not disclosedParabilis Medicines
Develops medicines targeting historically undruggable protein targets in cancer
$305MSeries F
Role not disclosed